Spots Global Cancer Trial Database for valacyclovir
Every month we try and update this database with for valacyclovir cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Oral Valganciclovir Versus Valacyclovir | NCT00562770 | Chronic Lymphoc... Leukemia | Valganciclovir Valacyclovir | 16 Years - | M.D. Anderson Cancer Center | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | NCT00589875 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | CAN-2409 Valacyclovir Temozolomide Radiation thera... | 18 Years - | Candel Therapeutics, Inc. | |
| Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | NCT05536349 | Leukemia | Pirtobrutinib Obinutuzumab Venetoclax Valacyclovir Allopurinol | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas | NCT00751270 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Oral Valganciclovir Versus Valacyclovir | NCT00562770 | Chronic Lymphoc... Leukemia | Valganciclovir Valacyclovir | 16 Years - | M.D. Anderson Cancer Center | |
| GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas | NCT03576612 | Glioma, Maligna... | AdV-tk Valacyclovir Radiation Temozolomide Nivolumab Laboratory Biom... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients | NCT00042328 | Neoplasms | Valacyclovir | 2 Years - 18 Years | Baylor College of Medicine | |
| ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation | NCT01972035 | Transplantation... Epstein-Barr Vi... Cytomegalovirus... | Valacyclovir Valganciclovir | - | University of Minnesota | |
| A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors | NCT00634231 | Malignant Gliom... Recurrent Epend... | AdV-tk valacyclovir Radiation | 3 Years - 21 Years | Candel Therapeutics, Inc. | |
| Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma | NCT00589875 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... High Grade Glio... | CAN-2409 Valacyclovir Temozolomide Radiation thera... | 18 Years - | Candel Therapeutics, Inc. | |
| Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery | NCT03541928 | High-risk Prost... Prostate Cancer | HSV-Tk Valacyclovir Bicalutamide Leuprolide Acet... Brachytherapy, ... Radical prostat... | 18 Years - | The Methodist Hospital Research Institute | |
| ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation | NCT01972035 | Transplantation... Epstein-Barr Vi... Cytomegalovirus... | Valacyclovir Valganciclovir | - | University of Minnesota | |
| AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) | NCT00638612 | Pancreatic Aden... Pancreatic Canc... | AdV-tk Valacyclovir | 18 Years - | Candel Therapeutics, Inc. | |
| Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) | NCT05536349 | Leukemia | Pirtobrutinib Obinutuzumab Venetoclax Valacyclovir Allopurinol | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
